The article deals with a review of the current literature on clinical use hepatoprotectors in drug-induced liver injury. was searched Scopus, Web Science, PubMed and other databases. Risk factors, pathogenetic mechanisms li­ver damage, international diagnostic criteria treatment for injuries are considered. Clinical pharmacological approaches to choice management injury substantiated. positive ...

Drugs may cause liver injury in a few susceptible individuals, but the molecular events that lead to this idiosyncratic, largely dose-independent and non-predictable drug-induced liver injury (DILI) are mostly unknown, since animal models to explore the pathogenetic mechanisms of human idiosyncratic DILI are not yet reliable.[...].

During metabolism in the liver the concentration of a drug or its metabolic products may be locally increased. This provides a theoretical basis for the large and ever-increasing number of reports of acute liver damage following drug therapy. If a drug or its metabolic product is a cellular poison we may expect a direct hepatotoxic reaction with a constant relationship to the level of drug in t...

To the Editor: An 84-year-old woman with a history of end-stage renal disease presented to the hospital with abdominal pain and bilious vomiting. On admission, she was found to have significant elevation in serum aminotransferases (AST 5 367 U/L and ALT 5 639 U/L,) and marginal elevation in alkaline phosphatase level (171 U/L). Basic metabolic panel was at her baseline. A thorough investigation...

Background Antituberculosis drugs (ATD) is the most common cause of drug-induce liver injury in many countries. While the mechanism of ATD-induced hepatitis is poorly understood, oxidative stress is suggested to be involved in the development of liver injury to drug metabolites. In this regards, we explored the possible associations between glutathione related enzymes (GCLM, GCLC and GSTP1) gen...

Drug-induced liver injury (DILI) is a leading cause of acute liver failure, and a major reason for the recall of marketed drugs. Detection of potential liver injury is a challenge for clinical management and preclinical drug safety studies, as well as a great obstacle to the development of new, effective and safe drugs. Currently, serum levels of alanine and aspartate aminotransferases are the ...

Elevations in serum bilirubin during drug treatment may indicate global liver dysfunction and a high risk of liver failure. However, drugs also can increase serum bilirubin in the absence of hepatic injury by inhibiting specific enzymes/transporters. We constructed a mechanistic model of bilirubin disposition based on known functional polymorphisms in bilirubin metabolism/transport. Using physi...